Aquestive Therapeutics Ownership
| AQST Stock | USD 3.97 0.26 6.15% |
Shares in Circulation | First Issued 2007-06-30 | Previous Quarter 91.2 M | Current Value 95.5 M | Avarage Shares Outstanding 43.5 M | Quarterly Volatility 24.2 M |
Aquestive | Build AI portfolio with Aquestive Stock |
Aquestive Stock Ownership Analysis
About 49.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.58. Aquestive Therapeutics had not issued any dividends in recent years. Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Aquestive Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 157 people. For more info on Aquestive Therapeutics please contact Keith Kendall at 908 941 1900 or go to https://www.aquestive.com.Aquestive Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aquestive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aquestive Therapeutics backward and forwards among themselves. Aquestive Therapeutics' institutional investor refers to the entity that pools money to purchase Aquestive Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2025-03-31 | 818.8 K | Northern Trust Corp | 2025-03-31 | 587.8 K | Two Sigma Advisers, Llc | 2025-03-31 | 576.4 K | Harvey Capital Management Inc | 2025-03-31 | 499.6 K | Citadel Advisors Llc | 2025-03-31 | 459.6 K | Bracebridge Capital, Llc | 2025-03-31 | 459.2 K | Woodline Partners Lp | 2025-03-31 | 407.7 K | Sio Capital Management, Llc | 2025-03-31 | 391.6 K | Stifel Financial Corp | 2025-03-31 | 375.1 K | Bratton Capital Management, L.p. | 2025-03-31 | 9.8 M | Blackrock Inc | 2025-03-31 | 5.9 M |
Aquestive Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aquestive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aquestive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aquestive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aquestive Therapeutics Outstanding Bonds
Aquestive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aquestive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aquestive bonds can be classified according to their maturity, which is the date when Aquestive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.